Read + Share
Nierengarten MB. FDA approves durvalumab for perioperative immunotherapy for patients with
muscle-invasive bladder cancer: In a prespecified analysis, the trial
demonstrated a statistically significant improvement in event-free survival and
overall survival. Cancer 2025;131:e35912.
PMID: 40607901
|
 |
|
